Hovione & Particle Sciences Inc. Ink Deal to Speed Up Drug Solubilization Projects
Hovione and Particle Sciences Inc (PSI) recently announced a collaboration agreement under which they will pool their technologies together to significantly speed development projects targeting poorly water-soluble drugs. The companies expect to jointly be able to significantly reduce typical project times.
HovioneÂand PSI are joining their solid solution technologies based on spray-drying capabilities and aimed at targeting ways to maximize the bioavailability of BCS Class II APIs. Development will be fast-tracked at both companies, with PSI developing the solubilization process and resulting drug product for their clients and Hovione managing the scale-up and industrialization of the spray-drying process.
“It is truly incredible how versatile and useful spray-drying technology is,” said Dave Hoffman, President, Hovione US Operations. “We have used it from a gram scale to tons, with important time savings on the scale-up to manufacture products where other technologies failed. Teaming up with PSI will give their customers an integrated solution that will allow us to go from drug product and process design to feasibility and development to industrial application in record time.”
“We have a variety of drug delivery platforms, some of which are best scaled through spray-drying,” added Mark Mitchnick, Particle Sciences’ CEO. “Our unique contribution is to develop products that maximize clinical effect, and after that, Hovione takes over with their technological and industrial expertise and regulatory compliance. We will really be able to save our clients quite a lot of time.”
Hovione is an international company with over 50 years’ experience in API development and compliant manufacture. With four FDA-inspected sites in the
Total Page Views: 903
